- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Therapeutic Approaches for Hepatitis C
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 1, Pages 78-88
Publisher
Springer Nature
Online
2013-10-14
DOI
10.1038/clpt.2013.206
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance
- (2013) Akbar Ali et al. ACS Chemical Biology
- Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure
- (2013) Quyen Ngo-Metzger et al. ANNALS OF INTERNAL MEDICINE
- Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C
- (2013) Dominique Larrey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study
- (2013) Kristi L. Berger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
- (2013) Paul J. Pockros et al. HEPATOLOGY
- Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial
- (2013) Mark S. Sulkowski et al. HEPATOLOGY
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients
- (2013) Heiner Wedemeyer et al. HEPATOLOGY
- Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
- (2013) Mark S. Sulkowski et al. HEPATOLOGY
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
- (2013) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses
- (2012) Judith M. Gottwein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
- (2012) Fumitaka Suzuki et al. JOURNAL OF CLINICAL VIROLOGY
- Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
- (2012) Dominique Larrey et al. JOURNAL OF HEPATOLOGY
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
- (2012) F. Poordad et al. JOURNAL OF VIRAL HEPATITIS
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
- (2012) Stanislas Pol et al. LANCET INFECTIOUS DISEASES
- A Watershed Moment in the Treatment of Hepatitis C
- (2012) Raymond T. Chung NEW ENGLAND JOURNAL OF MEDICINE
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic hepatitis C: Treatments of the future
- (2012) Marc Bourlière et al. Clinics and Research in Hepatology and Gastroenterology
- Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
- (2011) Michael Manns et al. ANTIVIRAL THERAPY
- Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
- (2011) Stefan Zeuzem et al. GASTROENTEROLOGY
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
- (2011) Stefan Zeuzem et al. HEPATOLOGY
- 1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA
- (2011) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSI-7851, a Pronucleotide of -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
- (2010) A. M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice
- (2010) Jeannette Cany et al. JOURNAL OF HEPATOLOGY
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
- (2010) Michael P. Manns et al. JOURNAL OF HEPATOLOGY
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
- (2010) Edward J Gane et al. LANCET
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Telaprevir for Previously Treated Chronic HCV Infection
- (2010) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review: New direct-acting antivirals in the development for hepatitis C virus infection
- (2010) Paul J. Pockros Therapeutic Advances in Gastroenterology
- Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- (2009) Henk W. Reesink et al. GASTROENTEROLOGY
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein
- (2008) Timothy L. Tellinghuisen et al. PLoS Pathogens
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now